Identification and characterization of driver gene(s) in recurrent lung cancer am

复发性肺癌驱动基因的鉴定和表征

基本信息

  • 批准号:
    7683237
  • 负责人:
  • 金额:
    $ 28.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-08 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We have completed analysis of over 250 lung cancer samples by a high- resolution genome profiling method developed here at Cold Spring Harbor Laboratory (CSHL). We found twelve major recurrent amplicons, most of which contain known driver genes such as MYC or KRAS2, and three others that do not, including the second most frequent amplicon which is located at 14q13. Our first specific aim is to perform comprehensive functional evaluation of all three candidate driver genes within this frequently amplified region at 14q13. This comprehensive functional evaluation will utilize both gain-of-function transformation assays and loss-of-function assays using new RNA interference technology, developed here at CSHL, that silences gene expression in vitro and in vivo. We have preliminary data that indicates that all three genes, each encoding a different transcription factors, synergistically promote the proliferation of lung epithelial cells. In addition to functional analysis, we have formed collaborations to address the potential diagnostic and prognostic significance of 14q13 amplification. The other two novel frequent amplicons contain several candidate genes. To address the difficulty inherent in functional analysis of amplicons containing many overexpressed genes, our second specific aim is to develop new barcoded RNA library interference technology, which enables functional analysis of many genes in parallel, into a robust tool for functional analysis of amplicons with large numbers of candidate driver genes. Our results will produce new insights into the molecular basis of lung carcinogenesis and should identify key therapeutic targets and new strategies for diagnostics for this highly lethal cancer. The first goal of this study focuses on the discovery and functional characterization of novel causal genes of one of the most deadly forms of lung cancer. The second goal is to create a gene function-based tool to enable researchers to rapidly identify the causal gene within a recurrent amplified genomic region that contains too many genes to be studied by a gene-by-gene approach. Forward research progress of this research proposal is expected to positively impact the diagnosis and treatment of lung cancer in the future.
描述(申请人提供):我们已经用冷泉港实验室(CSHL)开发的高分辨率基因组图谱方法完成了对250多个肺癌样本的分析。我们发现了12个主要的重复扩增,其中大多数包含已知的驱动基因,如MYC或KRAS2,另外3个不包含,包括位于14q13的第二频繁扩增。我们的第一个特定目标是在14q13对这个频繁扩增区域内的所有三个候选驱动基因进行全面的功能评估。这项全面的功能评估将利用CSHL在这里开发的新的RNA干扰技术,利用功能获得转化分析和功能丧失分析,在体外和体内沉默基因表达。我们有初步数据表明,这三个基因,每个编码不同的转录因子,协同促进肺上皮细胞的增殖。除了功能分析,我们还合作解决了14q13扩增的潜在诊断和预后意义。另外两个新的频繁扩增片段包含几个候选基因。为了解决包含许多过表达基因的扩增片段的功能分析固有的困难,我们的第二个具体目标是开发新的条形码RNA文库干扰技术,使多个基因的功能分析成为一种强大的工具,用于包含大量候选驱动基因的扩增片段的功能分析。我们的结果将对肺癌发生的分子基础产生新的见解,并将确定这种高度致命的癌症的关键治疗靶点和新的诊断策略。这项研究的第一个目标是发现最致命的肺癌之一的新的致病基因及其功能特征。第二个目标是创建一种基于基因功能的工具,使研究人员能够在重复扩增的基因组区域中快速识别原因基因,该基因组区域包含太多基因,无法通过逐个基因的方法进行研究。本研究方案的前瞻性研究进展有望对未来肺癌的诊断和治疗产生积极影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Mu其他文献

David Mu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Mu', 18)}}的其他基金

Modifier of Cancer Sensitivity to Statins
癌症对他汀类药物敏感性的调节剂
  • 批准号:
    9101012
  • 财政年份:
    2016
  • 资助金额:
    $ 28.96万
  • 项目类别:
Modifier of Cancer Sensitivity to Statins
癌症对他汀类药物敏感性的调节剂
  • 批准号:
    9251790
  • 财政年份:
    2016
  • 资助金额:
    $ 28.96万
  • 项目类别:
Identification and characterization of driver gene(s) in recurrent lung cancer am
复发性肺癌驱动基因的鉴定和表征
  • 批准号:
    7846461
  • 财政年份:
    2009
  • 资助金额:
    $ 28.96万
  • 项目类别:
Identification and characterization of driver gene(s) in recurrent lung cancer am
复发性肺癌驱动基因的鉴定和表征
  • 批准号:
    8301736
  • 财政年份:
    2008
  • 资助金额:
    $ 28.96万
  • 项目类别:
Identification and characterization of driver gene(s) in recurrent lung cancer am
复发性肺癌驱动基因的鉴定和表征
  • 批准号:
    8113429
  • 财政年份:
    2008
  • 资助金额:
    $ 28.96万
  • 项目类别:
Identification and characterization of driver gene(s) in recurrent lung cancer am
复发性肺癌驱动基因的鉴定和表征
  • 批准号:
    7877859
  • 财政年份:
    2008
  • 资助金额:
    $ 28.96万
  • 项目类别:
Identification and characterization of driver gene(s) in recurrent lung cancer am
复发性肺癌驱动基因的鉴定和表征
  • 批准号:
    7380927
  • 财政年份:
    2008
  • 资助金额:
    $ 28.96万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了